OOIR: Observatory of International Research

Papers

(The TQCC of Lancet Haematology is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Towards reparatory measures: blood donation, health systems, and men who have sex with men	294
In the trenches	229
Zanubrutinib-associated ecchymotic lesions	215
Prioritising health equity alongside donation safety – Authors' reply	195
Correction to Lancet Haematol 2023; 10: e333–45	164
Correction to Lancet Haematol 2023; published online Aug 28. https://doi.org/10.1016/S2352-3026(23)00164-3	161
Correction to Lancet Haematol 2024; 11: e114–26	138
Monoclonal B-cell lymphocytosis, monoclonal gammopathy of undetermined significance, and T-cell clones of uncertain significance: are these premalignant conditions sharing a common identity?	134
Retinal haemorrhage as a complication of blastic plasmacytoid dendritic cell neoplasm	128
Another quadruplet therapy for multiple myeloma: the beginning of the end for autologous haematopoietic stem-cell transplantation?	114
Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts	113
Managing haematological malignancies in pregnant women	112
MRD-guided treatment cessation in multiple myeloma	108
Is there still a role for CNS prophylaxis in diffuse large B-cell lymphoma?	107
Optimising communication to patients with venous thromboembolism: development of a provider toolkit	105
Vaccine efficacy and iron deficiency: an intertwined pair?	94
Alloimmunisation against red blood cells in sickle cell disease: transfusion challenges in high-income and low-income countries	93
Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial	88
International Society on Thrombosis and Haemostasis Congress 2023	86
Venetoclax with intensive chemotherapy in younger patients with acute myeloid leukaemia	82
Be compliant or compromise?	82
The HemeOncBuddy app—a new tool to keep up with the clinical trial storm	75
Bedside art is good medicine	74
Artwork from trauma: the social life of medical data	71
Sequencing therapies in Hodgkin lymphoma	71

CAR T cells in CNS-relapsed leukaemia: one step forward	69
Blinatumomab plus hyper-CVAD: the prelude to a new era in acute lymphocytic leukaemia	68
Idiopathic multicentric Castleman disease with arteriolar endotheliopathy and secondary haemophagocytosis	65
Rituximab versus active surveillance in patients with follicular lymphoma	65
Epidemiology, clinical features, and outcomes of peripheral T-cell lymphoma in Latin America: an international, retrospective, cohort study	65
25 mm Hg versus 35 mm Hg elastic compression stockings to prevent post-thrombotic syndrome after deep vein thrombosis (CELEST): a randomised, double-blind, non-inferiority trial	64
Blood deserts: a vision to tackle blood inaccessibility	63
Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study	63
Living with sickle cell disease: voices from sub-Saharan Africa	61
Blood cell defence against pathogens	60
Correction to Lancet Haematol 2023; 10: e433–44	59
Call to action: equitable comprehensive care for patients with sickle cell disease in the USA	59
Production and supply of blood products in Brazil	58
Eltrombopag–cyclosporin A in treating severe aplastic anaemia	58
Racial and ethnic survival disparities in patients with haematological malignancies in the USA: time to stop ignoring the numbers	56
Methodological challenges in the development of endpoints for myelofibrosis clinical trials	55
Update on SickleInAfrica: a collaborative and multidimensional approach to conduct research and improve health	55
Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the past	55
Variations in antenatal management and outcomes in haemolytic disease of the fetus and newborn: an international, retrospective, observational cohort study	54
Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological malignancies: an international, randomised, double-blind, placebo-controlled, phase 3 trial	52
Sickle cell disease in India: current status and progress	50
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, ran	50
Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective	50
Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study	50
Could improving mental health disorders help increase cancer survival?	49
Universal health coverage for children with cancer	49
Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations	49
Vacuoles in bone marrow progenitors: VEXAS syndrome and beyond	48
Vodobatinib for patients with Philadelphia chromosome-positive chronic myeloid leukaemia resistant or intolerant to multiple lines of previous therapy: an open-label, multicentre, phase 1/2 trial	48
Early switch to oral anticoagulation in patients with acute intermediate-risk pulmonary embolism (PEITHO-2): a multinational, multicentre, single-arm, phase 4 trial	48
Correction to Lancet Haematol 2022; Published online July 27. https://doi.org/10.1016/S2352-3026(22)00206-X	47
Targeting CD70 in acute myeloid leukaemia: an emerging therapeutic angle in combinatorial treatment	47
Progressive multifocal leukoencephalopathy in the era of chimeric antigen receptor T-cell therapy	47
Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study	47
Correction to Lancet Haematol 2022; 9: e200–07	46
Global effort to evacuate Ukrainian children with cancer and blood disorders who have been affected by war	44
Oreofe Odejide—aiming to raise the bar in haematology care	44
Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial	44
Beyond maximum grade: advancing the measurement and analysis of adverse events in malignant haematology trials in the modern era	44
Correction to Lancet Haematol 2024; 11: e310–11	43
[18F]FDG-PET-CT compared with CT for persistent or recurrent neutropenic fever in high-risk patients (PIPPIN): a multicentre, open-label, phase 3, randomised, controlled trial	43
Sickle cell disease—unity and patient-centred education	41
Addressing inequity in access to palliative care for patients with non-malignant or benign haematological diseases	41
Thank you to our 2022 peer reviewers and an update on inclusion and diversity	41
CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials	41
A long-awaited benchmark in lymphomatoid granulomatosis	41
Lakshmi Nayak: striving to contain the brain's deadliest killers	40
The rollercoaster of vaccine-induced immune thrombotic thrombocytopenia	40
Secondary haematological malignancies	40
Reporting of trials with possible detrimental overall survival: a patient advocate perspective	39

Should patients with haemophilia receive gene therapy?	38
Striking the right balance	38
Elotuzumab: no additional effect in patients with newly diagnosed multiple myeloma	37
Haemophilia—unparalleled progress but inadequate access	37
2024 ASH Annual Meeting	36
Haematology and climate change	36
Survival and quality of life in patients with lower risk myelodysplastic syndromes exposed to erythropoiesis-stimulating agents: an observational cohort study	36
In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospecti	36
Beyond remission: secondary primary malignancies in patients with lymphoma after autologous haematopoietic stem-cell transplantation	35
Correction to Lancet Haematol 2024; 11: e521–29	34
Comparison of international guideline recommendations for the diagnosis of pulmonary embolism	34
Efficacy or convenience? Subcutaneous blinatumomab as a promising new treatment for B-cell acute lymphoblastic leukaemia	34
The challenge of defining the global burden of iron deficiency anaemia	34
Patients first: improving toxicity assessment and reporting	33
Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-lab	33
Crizanlizumab with or without hydroxyurea in patients with sickle cell disease (STAND): primary analyses from a placebo-controlled, randomised, double-blind, phase 3 trial	32
Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management	32
Removing unfair barriers to blood donation	31
Can defibrotide prophylaxis prevent sinusoidal obstruction syndrome following haematopoietic stem-cell transplantation?	31
In defence of individualised medicine	30
Life beyond blood disorders	30
Thank you to The Lancet Haematology's peer reviewers in 2022	30
The case for equitable haemophilia care	29
The Lancet Haematology at 10	29
The impact of patient ethnicity on haematopoietic cell transplantation outcome: a retrospective cohort study on the UK experience	29
Anti-BCMA/GPRC5D bispecific CAR T cells for relapsed or refractory multiple myeloma: is 1 + 1 greater than 2?	28
Integrated molecular and immunological features of human T-lymphotropic virus type 1 infection and disease progression to adult T-cell leukaemia or lymphoma	28
Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b/2 study	28
Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7)	26
Breaking sex biases: access for all in haemophilia care	26
Management of pregnancies with anti-K alloantibodies and the predictive value of anti-K titration testing	26
Sovleplenib in immune thrombocytopenia	26
Bexmarilimab plus azacitidine for high-risk myelodysplastic syndrome and relapsed or refractory acute myeloid leukaemia: results from the dose-escalation part of a multicentre, single-arm, phase 1/2 t	26
Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow	25
Haematopoietic stem-cell transplantation in older adults: geriatric assessment, donor considerations, and optimisation of care	25
Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group	25
Beyond maximum grade: introduction to The Lancet Haematology Adverse Events Reporting Series	25
Artificial intelligence in peripheral blood films: an evolving landscape	25
Gene therapy in China: past, present, and future	25
Melflufen in multiple myeloma: the conclusion matters	24
Acquired haemophilia in an Edo period Japanese surgical casebook	24
A rare blood disorder that created a watercolour storytelling movement	24
A treatise on clinical trials	24
Riociguat in patients with sickle cell disease and hypertension or proteinuria (STERIO-SCD): a randomised, double-blind, placebo controlled, phase 1–2 trial	23
Needles were the least of my worries	23
Clinical trial design change implementation for inclusive studies	22
Ask, do not tell: consulting a patient advisory board to understand unmet needs of patients with GVHD in Europe	22
Monumen-TAL progress in the treatment of relapsed multiple myeloma	22
Mental health disorders and survival among older patients with diffuse large B-cell lymphoma in the USA: a population-based study	22
Don Thomas: leading the charge to bone marrow transplantation	21
Iron deficiency anaemia in sub-Saharan Africa: a review of current evidence and primary care recommendations for high-risk groups	21
Virtual twins for personalised CAR T-cell therapy in myeloma	21
Heavy menstrual blood loss in patients with von Willebrand disease: an unsolved problem	21
Making a case for disease-modifying agents in myelofibrosis	21
The effects of upward revision of haemoglobin thresholds for anaemia in blood donations	21
Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study	21
Lines of the haematology community	20
COVID-19 vaccination antibody responses in patients with aplastic anaemia and paroxysmal nocturnal haemoglobinuria	20
Oleksandr Lysytsia: the war in Ukraine has changed everything about our lives	20
Patients receiving allogeneic haematopoietic stem-cell transplantation and clinical outcomes after early access to palliative care	20
Reducing toxic waste: improving toxicity capture in childhood cancer	20
Optimising maintenance therapy after transplantation: sorafenib's role in patients with FLT3-ITD acute myeloid leukaemia	20
UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation t	20
Antifibrinolytics do not add to the benefits of platelet transfusion	19
Improved survival and enhanced quality of life through anaemia correction in lower risk myelodysplastic syndromes: meaningful insights from an EUMDS Registry study	19
Making blood count	19
Mitapivat for treatment of pyruvate kinase deficiency	19
Epistemic limitations of measurable residual disease in haematological malignancies	19
Immunochemotherapy for life-threatening haematological malignancies in pregnancy: a systematic review of the literature and cross-sectional analysis of clinical trial eligibility	19
The effects of revised haemoglobin cutoffs on the global burden of anaemia	18
Low-dose dasatinib: when less can be more	18
A comprehensive approach to therapy of haematological malignancies in older patients	18
Haematological malignancies in sub-Saharan Africa: east Africa as an example for improving care	17
Short versus extended treatment with a carbapenem in patients with high-risk fever of unknown origin during neutropenia: a non-inferiority, open-label, multicentre, randomised trial	17
Incidence and prognosis of superficial vein thrombosis during pregnancy and the post-partum period: a Danish nationwide cohort study	17
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study	16
Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study	16
Regional empowerment through decentralised governance under a centralised regulatory system facilitates the development of cellular therapy in China	16
Brentuximab vedotin with AVD for stage II–IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial	16
CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose e	16

Correction to Lancet Haematol 2021; 8: e55–66	15
Rosline Hassan: building the future of haemato-pathology in Malaysia	15
Lallindra Gooneratne—maintaining treatment flow amid crisis	15
Effect of rituximab on immune status in children with mature B-cell non-Hodgkin lymphoma: a prespecified secondary analysis of the Inter-B-NHL Ritux 2010 trial	15
Time to define and refine maintenance strategies in acute myeloid leukaemia	15
Reactivating hope for TP53-mutated acute myeloid leukaemia?	14
Long-term data from the REACH study testing hydroxyurea to treat sickle cell anaemia in children in sub-Saharan Africa	14
Correction to Lancet Haematol 2024; 11: e862–72	14
Long term strategies for individuals with sickle cell disease	14
Rituximab biosimilars for B-cell lymphomas: a decade of real-world experience from India	13
Public health and programme development in sickle cell disease in Ghana: the legacy of Kwaku Ohene-Frempong	13
Sexually transmitted infections in the context of haematological malignancies	13
Haematology in sub-Saharan Africa: advances and opportunities in health care, education, and research	13
Pembrolizumab and low-dose, single-fraction radiotherapy for patients with relapsed or refractory multiple myeloma: a prospective, single-centre, single-group, open-label, phase 2 pilot trial in the U	13
Treatment approaches for patients with TP53-mutated mantle cell lymphoma	13
Correction to Lancet Haematol 2023; 10: e203–12	13
An integrated approach to cardioprotection in lymphomas	13
Conditioning regimens for HSCT for patients with high-risk myelodysplastic syndrome and secondary acute myeloid leukaemia	13
Haemoglobin thresholds to define anaemia from age 6 months to 65 years: estimates from international data sources	13
Melflufen in multiple myeloma: the conclusion matters – Authors' reply	13
Iron deficiency anaemia—an ongoing challenge	13
The value of anti-CD30 CAR T cells in Hodgkin lymphoma	12
Follicular lymphoma: is more better or is less really more?	12
Correction to Lancet Haematol 2023; 10: e713–34	12
Isolated IgG4-related disease of the left maxillary antrum	12
Under-recognition of measurement and management of serum ferritin among populations at high risk of iron deficiency – Authors' reply	12
Oncology service priorities for the new UK Government	11
Is dose-adjusted EPOCH-R the new standard for high-risk Burkitt lymphoma?	11
Should patients with Ph-negative acute lymphoblastic leukaemia who reach minimal residual disease negativity have HSCT?	11
Virginia Abello Polo—a once-in-a-lifetime opportunity	11
Should patients with Ph-negative acute lymphoblastic leukaemia who reach minimal residual disease negativity have HSCT?	11
Prehospital blood transfusion for haemorrhagic shock – Authors' reply	11
Risk stratified management approaches for smouldering multiple myeloma: clinical research becomes clinical practice	10
Fitusiran prophylaxis in severe haemophilia without inhibitors	10
Renal colocalisation of Rosai-Dorfman-Destombes disease and secondary AA amyloidosis successfully treated with lenalidomide and dexamethasone	10
Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial	10
Concerns on perioperative anaemia management in the FIT trial	10
Correction to Lancet Haematol 2025; 12: e128–37	10
Safe blood supply in sub-Saharan Africa: challenges and opportunities	10
Inequalities in the career pathway for paediatric HSCT and cellular therapy physicians	10
Under-recognition of measurement and management of serum ferritin among populations at high risk of iron deficiency	10
CAR T-cell therapies in China: rapid evolution and a bright future	10
Resuscitation with blood products in patients with trauma-related haemorrhagic shock receiving prehospital care (RePHILL): a multicentre, open-label, randomised, controlled, phase 3 trial	9
Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study	9
Correction to Lancet Haematol 2024; 11: e38–50	9
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomise	9
Iadademstat in combination with azacitidine in patients with newly diagnosed acute myeloid leukaemia (ALICE): an open-label, phase 2a dose-finding study	9
Mental health and psychological resilience in sickle cell disease	9
Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study	9
Correction to Lancet Haematol 2024; 11: e510–20	9
Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study	9
Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial	9
Defibrotide prophylaxis for prevention of sinusoidal obstruction syndrome	9